Embryonic stem cell-derived cardiac myocytes are not ready for human trials

Circ Res. 2014 Jul 18;115(3):335-8. doi: 10.1161/CIRCRESAHA.114.304616. Epub 2014 Jun 16.

Abstract

Recently a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a non-human primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Animals
  • Embryonic Stem Cells / cytology*
  • Heart*
  • Humans
  • Male
  • Myocardial Infarction / pathology*
  • Myocardial Infarction / therapy*
  • Myocytes, Cardiac / cytology*
  • Regeneration*